What Is Egrifta?

1. What does the label cover?

Both current labels approve Egrifta for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (Egrifta WR label). Lipodystrophy here means an abnormal redistribution of body fat seen in some people on long-term HIV treatment, often with fat building up inside the abdomen.

The label adds three limits of use:

• long-term cardiovascular safety has not been established, and continuing treatment should be weighed in people whose visceral fat has not fallen;
• it is not indicated for weight loss management, because its effect on weight is neutral;
• there are no data showing it improves adherence to HIV medicines.

It is also not indicated for children. In children with open growth plates, the label warns it could cause excessive growth.

2. How do Egrifta, Egrifta SV and Egrifta WR differ?

All three contain the same molecule and are injected once a day, as described in the Egrifta SV label and the Egrifta WR label. They differ in vial size, dose, how often the powder is mixed and how it is stored.

The doses look different but the exposure is the same. The WR label says a 1.28 mg dose of WR gives similar blood levels to the original 2 mg dose, and the Theratechnologies approval release says pharmacokinetic studies showed bioequivalence to the original formulation. Both labels state plainly that SV and WR are not substitutable, because the dose, the number of vials, the mixing steps and the storage all differ.

A WR box holds 4 vials of 11.6 mg, a 30 mL bottle of bacteriostatic water and a 28-day supply of syringes and needles. An SV box holds 30 single-dose 2 mg vials and 30 bottles of sterile water. WR’s bacteriostatic water contains benzyl alcohol as a preservative, and a mixed WR vial is kept at room temperature for 7 days. The release also says WR needs less than half the injection volume of SV.

The labels say to inject into the abdomen, rotating sites, and not into scar tissue, bruises or the navel. These are label instructions for prescribed product; preparing doses is something a clinician or pharmacist teaches with the product’s own instructions.

3. What did the trials show?

Egrifta WR’s approval rests on the trials of the original 2 mg Egrifta plus the bioequivalence data (Egrifta WR label). Two phase 3 trials enrolled adults aged 18 to 65 on stable HIV treatment, with a large waist and waist-to-hip ratio and fasting glucose below 150 mg/dL. People with diabetes on medication, a history of cancer or hypopituitarism were excluded. The main outcome was the change in visceral adipose tissue (VAT), fat inside the abdomen, measured by CT scan.

Falutz and colleagues’ pooled analysis of both trials, 806 people in all, found a treatment effect of −15.4% on VAT. Fat under the skin of the abdomen did not change significantly (treatment effect −0.6%). Triglycerides fell (treatment effect −12.3%), as did the total-to-HDL cholesterol ratio, and people reported less distress about their belly appearance. In the group that stayed on Egrifta to week 52, VAT was 17.5% below baseline.

Not everyone responds. A post hoc analysis by Stanley and colleagues defined responders as people whose VAT fell by at least 8%. Responders had larger triglyceride falls and kept glucose and HbA1c steadier over 52 weeks, while in non-responders fasting glucose rose by a mean of 8 mg/dL at week 52. The label’s advice to reconsider treatment when VAT has not fallen reflects this split.

What happens after stopping

In the extension phase, people who had taken Egrifta for 26 weeks were re-randomized to continue or switch to placebo (Egrifta WR label).

The fat returned within six months of stopping. Egrifta works only while it is taken.

Liver fat

Two NIH-funded trials, separate from the approval program, looked at liver fat in people with HIV. In a 6-month JAMA trial of 50 people, the original 2 mg dose cut VAT by 42 cm² more than placebo and reduced liver fat by a net 2.9 percentage points. In a 12-month Lancet HIV trial of 61 people with fatty liver disease, liver fat fell by an absolute 4.1 percentage points more than placebo, a 37% relative reduction, and 35% versus 4% ended with liver fat below the 5% threshold. Glucose and HbA1c did not differ at 12 months. Neither trial changed the label, which covers abdominal fat only.

4. What are the side effects and warnings?

Across the clinical program, 740 people received Egrifta, 543 of them in the 26-week placebo-controlled phase (Egrifta WR label).

The label’s warnings section reports injection site reactions, including redness, itching, pain, irritation and bruising, in 25% versus 14% over 26 weeks, using a broader grouping than the table. Its other main warnings:

Antibodies to tesamorelin developed in about half of users, and in 85% of those with hypersensitivity reactions, but visceral fat and IGF-1 responses were similar with and without them.

The four contraindications are a disrupted hypothalamic-pituitary axis (from pituitary surgery, hypopituitarism, a pituitary tumor, head radiation or head trauma), active cancer, known hypersensitivity, and pregnancy. Pregnancy is excluded because reducing visceral fat offers no benefit then and could harm the fetus; in rats, high doses caused hydrocephaly in offspring. The pituitary contraindication follows from how the drug works: it acts through the pituitary, so it has nothing to act on if the pituitary is damaged.

5. Interactions, blood sugar and GLP-1 drugs

The label lists two interaction areas. Egrifta raises GH, and GH can change how fast the liver clears drugs processed by CYP450 enzymes, such as steroids, anticonvulsants and cyclosporine. And people on glucocorticoid replacement for adrenal insufficiency may need higher doses, especially with cortisone acetate or prednisone. In formal studies, Egrifta changed simvastatin levels by 15% or less and ritonavir, an HIV booster, by about 10%.

GLP-1 drugs are not mentioned, and no trial has combined Egrifta with semaglutide or tirzepatide. The two do different jobs. Egrifta was weight-neutral in its trials and targets visceral fat specifically; GLP-1 drugs reduce appetite and total body weight. In people with HIV, the SLIM LIVER trial (ACTG A5371), an open-label single-arm phase 2b study, gave semaglutide 1 mg weekly to adults with HIV and fatty liver disease; that is separate evidence and does not test the combination.

The practical overlap is glucose. Egrifta can raise blood sugar and increased the rate of new diabetes in its trials, while GLP-1 drugs lower it. Anyone on both would need glucose monitoring, and starting both at once would make it hard to tell which drug caused a change in weight, waist size or glucose. The tesamorelin guide covers the comparison with GLP-1 drugs in more detail, and the GLP-1 and muscle loss guide covers lean mass during weight loss.

6. Regulatory history, supply and ownership

The EMA’s committee had provisionally concluded that the benefits did not outweigh the risks. It found it hard to separate lipodystrophy-related abdominal fat from obesity-related fat, judged the fat reduction not shown to be clinically meaningful, noted that trial patients did not resemble European patients with HIV, and treated rising IGF-1 and missing long-term safety data as a major concern (EMA).

During the transition, SV stays available while insurers add coverage for WR, according to the September 2025 launch report. I did not find an official SV discontinuation date as of November 2026.

7. Egrifta versus unapproved tesamorelin

Tesamorelin is widely sold online as a research peptide. Those products are not Egrifta: they have no FDA-approved label, and their content, purity and sterility are not verified. The tesamorelin guide covers the FDA’s position on compounded and unapproved products. In sport, tesamorelin is named in class S2.2.4 of the WADA 2026 Prohibited List, prohibited at all times as a non-Specified Substance.

The trial evidence above applies to adults with HIV, abdominal fat buildup and no diabetes requiring medication. It does not establish results in people without HIV or in lean, trained people.

8. What should be recorded?

For a prescribed user, the label’s monitoring points translate into a short record: formulation (SV or WR, since they are not interchangeable), daily dose, the date a WR vial was mixed (it is discarded after 7 days), injection site, and the dates and results of IGF-1, glucose and HbA1c tests. Waist size is worth logging, since the trials measured it, but visceral fat itself needs a scan, and in the trials scale weight barely moved. Swelling, joint pain, hand numbness and any rash belong in the same log. The peptide tracker vs spreadsheet guide covers ways to keep those records together.

9. Egrifta FAQ

• What is Egrifta used for?

  Egrifta (tesamorelin) is FDA-approved for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The label adds that it is not indicated for weight loss, that long-term cardiovascular safety is not established, and that there are no data showing it improves adherence to HIV medicines.

• What is the difference between Egrifta SV and Egrifta WR?

  Both are injected under the skin once a day. Egrifta SV uses a 2 mg vial mixed with 0.5 mL of sterile water each day, giving a 1.4 mg dose, with the rest discarded. Egrifta WR uses an 11.6 mg vial mixed once with bacteriostatic water and kept at room temperature for 7 days of 1.28 mg doses. The labels say they are not substitutable.

• Does Egrifta cause weight loss?

  No. In the phase 3 trials, body weight changed by less than 1 kg in either direction. Egrifta reduces visceral fat, the fat around the organs, and the label calls its effect weight neutral and says it is not indicated for weight management.

• What happens when you stop Egrifta?

  The visceral fat tends to return. In the trials' extension phase, people switched from Egrifta to placebo regained visceral fat over 26 weeks, rising 22% and 16% from their week-26 levels, while those who continued held their reduction.

• What are the side effects of Egrifta?

  The most common were injection site reactions, joint pain, limb pain, muscle pain and swelling. Hypersensitivity reactions such as rash and hives occurred in 4%. The label also warns about raised IGF-1, fluid retention, carpal tunnel syndrome and a higher risk of diabetes (HbA1c of 6.5% or more in 5% vs 1% on placebo).

• Is Egrifta the same as the tesamorelin sold online?

  No. Egrifta is an FDA-approved prescription product with a verified formulation and label. Products sold online as research peptides are not approved, and their content and purity are not verified by the FDA.

• Can Egrifta be used with semaglutide or tirzepatide?

  No trial has tested the combination, and the Egrifta labels do not mention GLP-1 drugs. Both affect glucose in different directions, since Egrifta can raise blood sugar, so any combination would need a prescriber's oversight and glucose monitoring.

• Is Egrifta approved in Europe?

  No. A marketing application was withdrawn in June 2012 after the EMA's committee provisionally concluded that the benefits did not outweigh the risks, citing an unclear clinical benefit and concerns about raised IGF-1 and missing long-term safety data.

10. Sources